EGFR and non-small cell lung carcinoma: When considering the specific alteration of our patient, one cohort study, reporting limited responses to osimertinib in EGFR exon 20 insertion-mutation NSCLC, included two cases with the 773-774HVdelinsLM alteration: one had a short stable disease (progression-free survival (PFS) of 3.2months), and one had a partial response with a PFS of 8.3 months (18).